DELVE
LIVE

Serial Number

98254371

Owner

PROLOGUE MEDICINES, INC.

Attorney

Christina M. Licursi

Filing Date

Nov 3, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DELVE Trademark

Serial Number: 98254371

DELVE is a trademark filed by PROLOGUE MEDICINES, INC. on November 3, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

PROLOGUE MEDICINES, INC. (3 trademarks)

55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE, MA 02142

Entity Type: 03

Flagship Labs 89, Inc. (3 trademarks)

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

November 3, 2023

Registration Date

Not Registered

Goods & Services

Medical research and development; research and development in the field of computational biology, bioinformatics, genetics, genomics, biotechnology, pharmaceuticals, and therapeutics; platform as a service (PaaS) featuring computer software platforms for drug discovery; pharmaceutical and biopharmaceutical research and development; drug development services, namely, pharmaceutical drug development services; development of pharmaceuticals and therapeutic agents for others, namely, development of pharmaceutical preparations and medicines; platform as a service (PaaS) featuring computer software platforms for enabling research and development of pharmaceutical data in the field of computational biology, bioinformatics, genetics, genomics, biotechnology and pharmaceuticals; DNA, RNA, and genomic analysis and sequencing services for medical research purposes; none of the foregoing relating to finding people scientific studies to participate in or recruiting participants for scientific studies

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceuticals for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 23, 2026 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 24, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 10, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 6, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 27, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 27, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 27, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 4, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 3, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 3, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 4, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 26, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 26, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 24, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 19, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Dec 6, 2023 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 27, 2023 NWOS